DRKS00033591尚未招募不适用
Exome Sequencing (Buccal Swabs Cohort) and Molecular Profiling (Blood Cohort and Skin Biopsy Cohort) in Patients with Hidradenitis Suppurativa (HS) - 0000-HS-CES-20130
European Hidradenitis Suppurativa Foundation e.V.0 个研究点目标入组 4,000 人开始时间: 2024年2月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 4,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •HS Patients Buccal Swab Cohort (exome sequencing)
- •1. Male or female, age 18 years or older at the screening/baseline visit.
- •2. Subjects must have the diagnosis of HS (in compliance with the Dessau criteria as modified in San Francisco) for at least one year (365 days) prior the screening/baseline visit.
- •3. HS lesions must be present in at least two distinct classical anatomic areas (e.g., left and right axilla; or left axilla and left inguino-crural fold)
- •4. Willing and able to comply with clinic visits and study-related procedures.
- •5. Provide informed consent signed by study patient.
- •6. Able to understand and complete study-related material.
- •Healthy Volunteers Buccal Swab/Blood/Skin Biopsy Cohorts (exome sequencing)
- •1. Male or female, age 18 years or older at the screening visit
- •2. Is judged by the investigator to be in good health based on medical history
- •3. Healthy volunteer weight and smoking habit may match with that of the HS patients
- •4. Willing and able to comply with clinic visits and study-related procedures
- •5. Provide informed consent signed by study patient.
- •6. Able to understand and complete study-related material.
- •HS Patients Blood/Skin Biopsy Cohorts (cellular and molecular profiling in moderate-to-severe HS)
- •1. Male or female, age 18 years or older at the screening visit.
- •2. Subjects must have the diagnosis of HS for at least one year (365 days) prior the baseline visit.
- •3. HS lesions must be present in at least two distinct anatomic areas (e.g., left and right axilla; or left axilla and left inguino-crural fold), one of which must be Hurley Stage II or Hurley Stage III.
- •4. IHS4=4 and <11 with or without draining tunnels (50% of the patients included in Blood/Skin Biopsy Cohorts)
- •5. IHS4=11 with total draining tunnel count =2 (50% of the patients included in Blood/Skin Biopsy Cohorts)
- •6. Willing and able to comply with clinic visits and study-related procedures.
- •7. Provide informed consent signed by study patient or legally acceptable representative.
- •8. Able to understand and complete study-related material.
排除标准
- •1. Presence of skin comorbidities (e.g. inverse psoriasis, epidermal inclusion cyst) that may interfere with study assessments for HS.
- •2. Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect the patient’s participation in the study. Examples include, but are not limited to, patients with short life expectancy, patients with uncontrolled diabetes, patients with cardiovascular conditions (eg, stage III or IV cardiac failure according to the New York Heart Association classification), severe renal conditions (eg, patients on dialysis), debilitating neurological conditions (eg, demyelinating diseases), active major autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other severe endocrinological, gastrointestinal, hepatobiliary, metabolic, pulmonary, or lymphatic diseases. The specific justification for patients excluded under this criterion will be noted in study documents.
- •3. Any other medical or psychological condition (including relevant laboratory abnormalities at screening) that, in the opinion of the investigator, may suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his/her participation in this study, may make patient’s participation unreliable, or may interfere with study assessments. The specific justification for patients excluded under this criterion will be noted in study documents.
- •4. Pregnant or breastfeeding women
- •5. Unable to provide informed consent
- •6. The 65 Blood/Skin Biopsy Cohort patients should not be under treatment.
研究者
相似试验
招募中
不适用
Whole exome sequencing analysis to identify molecular targets in malignant lymphomaMalignant LymphomaJPRN-UMIN000013723ational Cancer Center Hospital East10
尚未招募
不适用
Whole Exome & Whole Genome Sequencing Analysis to Explore Familial Keratoconuseye bulging10002693NL-OMON53921Erasmus MC, Universitair Medisch Centrum Rotterdam
已完成
不适用
Whole exome sequencing in patients with Idiopathic Ventricular Fibrillation and familial Atrial Fibrillatioatrial fibrillation of unknown originlife-threatening ventricular rythm disorder of unknown origin10007510NL-OMON42277niversitair Medisch Centrum Utrecht70
已完成
不适用
Exome sequencing of consanguineous couples 1: Proof of principlecarriers of autosomal recessive disease alleles10083624NL-OMON37790Vrije Universiteit Medisch Centrum10
尚未招募
不适用
Whole genome sequencing and gene polymorphism analysis of aggressive periodontitisaggressive periodontitisJPRN-UMIN000046212Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan40